Abbvie Stock News

Foundation Resource Management Inc. lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 0.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,111 shares of the companys stock after selling 200 shares during the quarter. AbbVie comprises 1.0% of Foundation Resource Management Inc.s portfolio, making []

Norman Fields Gottscho Capital Management LLC cut its holdings in AbbVie Inc. (NYSE:ABBV) by 2.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,988 shares of the companys stock after selling 100 shares during the quarter. Norman Fields Gottscho Capital Management []

Pensionfund DSM Netherlands lowered its stake in shares of AbbVie Inc. (NYSE:ABBV) by 52.6% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 25,400 shares of the companys stock after selling 28,200 shares during the quarter. Pensionfund DSM Netherlands holdings in AbbVie were worth $2,740,000 at the end of the most recent reporting period. []

The ABBVIE POLITICAL ACTION COMMITTEE successfully filed their F3XN NOVEMBER MONTHLY with the coverage period of 10/01/2021 to 10/31/2021 and a confirmation ID of FEC-1549274 *********CommitteeId: C00536573 | FilingId: 1549274 | FormType: F3XN | CoverageFrom: 10/01/2021 | CoverageThrough: 10/31/2021 | ReportType: NOVEMBER MONTHLY*********

IFG Advisory LLC raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 2.4% during the 3rd quarter, Holdings Channel.com reports. The fund owned 23,900 shares of the companys stock after purchasing an additional 571 shares during the quarter. IFG Advisory LLCs holdings in AbbVie were worth $2,578,000 as of its most recent filing with []

Brokerages forecast that AbbVie Inc. (NYSE:ABBV) will report $3.31 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for AbbVies earnings, with the highest EPS estimate coming in at $3.36 and the lowest estimate coming in at $3.27. AbbVie reported earnings per share of $2.92 during []

LOWER GWYNEDD, Penn. , Nov. 19, 2021 /PRNewswire/ -- Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addition, the funding will also be used to accelerate the CMC and IND development of multiple other oncology pipelines and the development of the company''s multicyclic intracellular peptide (MIP) programs. Tavotek Biotherapeutics, established in early 2019, is committed to using innovation to improve the well-being of patients with unmet medical needs. The company has two R&D centers: one in Lower Gwynedd, Pennsylvania and another in Suzhou, China.

The average yield for 9 large pharmaceutical companies is 3.27% Related Stocks: LLY , GSK , BMY , PFE , AZN , ABBV , GILD , JNJ , SNY , PJP ,

First Hawaiian Bank grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,012 shares of the companys stock after purchasing an additional 734 shares during the period. First Hawaiian Banks holdings in AbbVie []

AbbVie (ABBV) has received the European Commissions (EC) approval for interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab) to be used separately or with methotrexate (MTX) The post AbbVies Gets EC Approval for SKYRIZI appeared first on Smarter Analyst .

AbbVie Announces First Provincial Reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for Patients…

Arthur M. Cohen & Associates LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 98.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,230 shares of the company’s stock after selling 254,422 shares during the quarter. Arthur M. Cohen & Associates LLC’s holdings […]

Inspirion Wealth Advisors LLC reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 230,427 shares of the companys stock after selling 583 shares during the period. AbbVie makes up 5.7% of Inspirion Wealth Advisors LLCs investment []

Related Stocks: HD , T , SRUUF , AFRM , PRVA , GLDG , MFMLF , SILEF , MCD , PEP , ENB , ABBV , GDXJ , UBER ,

Probity Advisors Inc. lowered its stake in AbbVie Inc. (NYSE:ABBV) by 3.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,699 shares of the companys stock after selling 758 shares during the quarter. Probity Advisors Inc.s holdings in AbbVie were worth $2,233,000 at the []